No response to recombinant human erythropoietin therapy in patients with congenital dyserythropoietic anemia type I

Pediatric Hematology and Oncology

Volumn 16, Issue 2, 1999, Pages 165-168

  Tamary, Hannah ^a,b   Shalev, Hanna ^c   Pinsk, Vered ^c   Zoldan, Meira ^a,b   Zaizov, Rina ^a,b  

^a SCHNEIDER CHILDREN S MEDICAL CENTER OF ISRAEL   (Israel)

^b TEL AVIV UNIVERSITY   (Israel)

^c BEN GURION UNIVERSITY OF THE NEGEV   (Israel)

Author keywords

Anemia; Congenital dyserythropoietic anemia type I; Recombinant human erythropoietin; Treatment

Indexed keywords

RECOMBINANT ERYTHROPOIETIN;

ADOLESCENT; ARTICLE; BONE MARROW DISEASE; CHILD; CLINICAL ARTICLE; DYSERYTHROPOIESIS; ERYTHROCYTE STRUCTURE; FEMALE; HEMOGLOBIN DETERMINATION; HISTOPATHOLOGY; HUMAN; HUMAN CELL; HUMAN TISSUE; MALE; PATHOGENESIS; PROTEIN BLOOD LEVEL; SUBCUTANEOUS DRUG ADMINISTRATION; TREATMENT FAILURE;

EID: 0032965427     PISSN: 08880018     EISSN: None     Source Type: Journal    
DOI: 10.1080/088800199277498     Document Type: Article

References (15)

1. Heimpel H, Wendt F. Congenital dyserythropoietic anemia with karyorrhexis and multinuclearity of crythroblasts. Helv Med Acta. 1968;34:103-115.
2. Lewis SM, Frisch B. Congenital dyserythropoietic anemias: electron microscopy. In: Congenital Disorders of Erythropoiesis. Ciba Foundation Symposium 37. Amsterdam: Elsevier; 1973:171-203.
3. Alter P, Young NS. The bone marrow failure syndromes. In: Nathan DJ, Oski FO, eds. Hematology of Infancy and Childhood. Vol. I. Philadelphia: Saunders; 1993:273.
4. Tamary H, Shalev H, Luria D, et al. Clinical features and studies of erythropoiesis in Israeli Bedouins with congenital dyserythropoietic anemia type I. Blood. 1996;87:1763-1770.
5. Eschbach JW. Erythropoietin: the promise and the facts. Kidney Int. 1994;45:70-76.
6. Spivak JL. Recombinant human erythropoietin and the anemia of cancer. Blood. 1994; 84:997-1004.
7. Schreiber S, Howaldt S, Schnoor M, et al. Recombinant erythropoietin for the treatment of anemia in inflammatory bowel disease. N Engl J Med. 1996;334:660-662.
8. Olivieri NF, Freedman MH, Perrine SP, et al. Trial of recombinant human erythropoietin: three patients with thalassemia intermedia. Blood. 1992;80:3258-3260 (letter).
9. Rachmilewitz EA, Aker M, Perry D, Dover G. Sustained increase in haemoglobin and RBC following long-term administration of recombinant human erythropoietin in patients with homozygous betathalassemia. Br J Haematol. 1995;90:341-345.
10. Cazzola M, Mercuirali F, Brugnara C. Use of recombinant human erythropoietin outside the setting of uremia. Blood. 1997;89:4248-4278.
11. Shalev H, Tamary H, Rezenitsky P, Zaizov R. Neonatal manifestations of congenital dyserythropoietic anemia type I. J Pediatr. 1997;131:95-98.
12. Williams WJ, Beutler E, Erslev AJ, Lichtmann MA (eds). Hematology. New York: McGraw-Hill; 1990: 1696-1738.
13. Wu H, Lin X, Jaenisch R, Lodish L. Generation of committed erythroid BFU-E and CFU-E progenitors does not require erythropoietin or the erythropoietin receptor. Cell. 1995;83:59-67.
14. Shannon KM, Keith JF 3rd, Mentzer WC, et al. Recombinant human erythropoietin stimulates erythropoiesis and reduces erythrocyte transfusions in very low birth weight preterm infants. Pediatrics. 1995;95:1-8.
15. Henry DH. Clinical application of recombinant erythropoietin in anemic cancer patients. Hematol Oncol Clin North Am. 1994;8:961-973.